
Trump officials are pushing psychedelic therapy. Will it help or hurt?
In the United States, a presidential administration finally seems to agree.
'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' US health secretary Robert F Kennedy Jr recently told members of Congress.
His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs.
The Trump administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants, and fluoride.
'I'm quite optimistic,' says Rick Doblin, whose organisation has pursed the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved'".
US regulators may reconsider MDMA
Under former US President Joe Biden, the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD), citing flawed data and questionable research.
Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first US approval of a psychedelic for medical use, and European researchers said it likely set the field back there as well.
But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval.
One new programme promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group.
That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill.
Links to psychedelic advocates
US health agencies also recently hired several new staffers with ties to the psychedelic movement.
'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies.
As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues.
But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science.
Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardise patients.
"If RFK and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science," Corlett said. 'I just don't think that's going to happen.'
Nora Volkow, the longtime director of the US National Institute on Drug Abuse, said her agency remains interested in psychedelics. It is funding a US drugmaker that's working to develop a safer, synthetic version of ibogaine, which is a potent psychedelic made from a shrub that's native to West Africa.
Texas recently launched a $50 million (€42.7 million) trial to test ibogaine as a treatment for opioid addiction, PTSD, and other conditions.
'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said.
'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them".
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


France 24
3 days ago
- France 24
US authorizes Juul to market vaping products
Juul won the new marketing granting orders (MGO) after submitting more than 110 scientific studies to the agency, the company said in a statement. The decision means Juul can continue to sell products that have been on the US market but in regulatory limbo following earlier actions by the FDA. "Following rigorous evaluation of the data, FDA decided that an MGO for the Juul System was 'appropriate for the protection of public health' –- the standard required by statute for authorization," Juul said. Juul has argued that its vaping products provide a public health benefit by shifting smokers away from combustible tobacco products closely linked to deadly illnesses. But the company has been criticized for its marketing practices, agreeing to pay $438.5 million in a 2022 settlement with 34 US states to resolve accusations of marketing to underage smokers. The FDA's move allows Juul to sell five products in all: the Juul device and capsules for the "Virginia Tobacco" and menthol flavor, each in versions with three or five percent nicotine concentration, said a spokesperson for the US Department of Health and Human Services. The products needed to meet the standard set under a 2009 smoking prevention law showing that the benefits of switching to a potentially less harmful product is "sufficient to outweigh the risks of the product," including to anyone not using tobacco products, the spokesperson said. The applicant submitted data "demonstrating high rates of adults completely switching from cigarettes to either the tobacco- or menthol-flavored Juul products." But the agency's determination "does not mean these tobacco products are safe, nor are they 'FDA approved,'" said the spokesperson, who added that the agency will continue to monitor Juul's compliance with youth marketing restrictions. Juul survived a difficult stretch after the FDA ordered it to halt sales in June 2022 because of health questions, although the decision was adminsistratively suspended by the same agency shortly thereafter. In June 2024, the FDA formally rescinded its June 2022 order, shifting the matter back into "pending" status while a substantive review continued. The FDA's action on Thursday "confirms that these products are now authorized to remain on the market," said a Juul spokesman.


France 24
3 days ago
- France 24
US health experts reassess hormone replacement therapy risks
HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes, vaginal discomfort, and pain during sex. But its use has plummeted in recent years amid concerns including a potential link to invasive breast cancer. Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, has long advocated for HRT, saying its risks have been overstated. "For decades, hormone replacement therapy for women -- that is estrogen or estrogen plus progesterone -- has helped women alleviate the symptoms of menopause, including hot flashes, dryness, mood swings, weight gain and poor sleep quality, to name a few," he said in a video ahead of the meeting. He added that when initiated within a decade of the onset of the transitional period before menopause, HRT may even reduce cognitive decline, the risk of Alzheimer's, and prevent osteoporosis and cardiovascular disease. Makary blamed the drop in HRT use on a landmark clinical trial, the Women's Health Initiative, which was halted in the early 2000s after it flagged increased risks of breast cancer and stroke. But he said subsequent studies had not replicated the findings on breast cancer. "The many benefits of hormone therapy were ignored as it was seen as a carcinogen. Prescriptions for hormone replacement therapy plummeted in the United States, women flushed their pills down the toilet," he said Thursday. "Fifty million plus women have not been offered the incredible potential health benefits of hormone replacement therapy because of medical dogma," he added, including his own mother, who suffered multiple bone fractures in her older life. Critics of the trial argue it was flawed because the participants were too far from menopause, when risks are elevated and benefits limited, and that the formulations used are now outdated. Label changes Still, the issue remains divisive within the medical community. The FDA's own warning label for HRT -- which can be administered through various means including orally, through skin patches, or vaginally -- cites risks including endometrial cancer, breast cancer, and life-threatening blood clots. This week, the American Family Physician journal published an editorial that found limited benefits and significant harms associated with HRT. "Menopause is a positive life experience for many women and should not be medicalized," the authors concluded. The nature of the FDA expert meeting is also unusual. Unlike standard practice before the Trump administration, no agenda was publicly posted. Several of the named panelists have ties to companies offering menopause treatments or who belong to the advocacy group "Let's Talk Menopause," which receives funding from pharmaceutical companies and campaigns to revise the FDA warning label.


France 24
3 days ago
- France 24
US health experts to reassess hormone replacement therapy risks
HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes and vaginal discomfort. But its use has plummeted in recent years amid concerns over rare side effects, including a potential link to invasive breast cancer. Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, has long advocated for HRT, saying its risks have been overstated. "For decades, hormone replacement therapy for women -- that is estrogen or estrogen plus progesterone -- has helped women alleviate the symptoms of menopause, including hot flashes, dryness, mood swings, weight gain and poor sleep quality, to name a few," he said in a video. He added that when initiated within a decade of the onset of the transitional period before menopause, HRT may even reduce cognitive decline, the risk of Alzheimer's, and prevent osteoporosis and cardiovascular disease. Makary blamed the drop in HRT use on a landmark clinical trial, the Women's Health Initiative, which was halted in the early 2000s after it flagged increased risks of breast cancer and stroke. But he said subsequent studies had not replicated the findings on breast cancer. Critics of the trial argue it was flawed because the participants were too far from menopause, and that the formulations used are now outdated. Still, the issue remains divisive within the medical community. The FDA's own warning label for HRT -- which can be administered through various means including orally, through skin patches, or vaginally -- cites risks including endometrial cancer, breast cancer, and life-threatening blood clots. This week, the American Journal of Physicians published an editorial that found limited benefits and significant harms associated with HRT. "Menopause is a positive life experience for many women and should not be medicalized," the authors concluded. The nature of the FDA expert meeting is also unusual. Unlike standard practice before the Trump administration, no agenda was publicly posted. Several of the named panelists have ties to companies offering menopause treatments or who belong to the advocacy group "Let's Talk Menopause," which receives funding from pharmaceutical companies and campaigns to revise the FDA warning label.